Polyethylene glycol-b-poly(lactic acid) polymersomes as vehicles for enzyme replacement therapy-Reference-Cited by-同舟云学术

Polyethylene glycol-b-poly(lactic acid) polymersomes as vehicles for enzyme replacement therapy

Published:2017-12 Issue:23 Volume:12 Page:2591-2606
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Kelly Jessica M¹²³,Gross Amanda L²⁴,Martin Douglas R²³⁴,Byrne Mark E¹³⁵

Affiliation:

1. Biomimetic & Biohybrid Materials, Biomedical Devices, & Drug Delivery Laboratories, Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, Auburn, AL 36849, USA

2. Scott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA

3. US Department of Education GAANN Graduate Fellowship Program in Biological & Pharmaceutical Engineering, Auburn University, Auburn, AL 36849, USA

4. Department of Anatomy, Physiology, & Pharmacology, Scott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA

5. Biomimetic & Biohybrid Materials, Biomedical Devices, & Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, Glassboro, NJ 08028, USA

Abstract

Aim: Polymersomes are created to deliver an enzyme-based therapy to the brain in lysosomal storage disease patients. Materials & methods: Polymersomes are formed via the injection method using poly(ethylene glycol)-b-poly(lactic acid) (PEGPLA) and bound to apolipoprotein E, to create a brain-targeted delivery vehicle. Results: Polymersomes have a smallest average diameter of 145 ± 21 nm and encapsulate β-galactosidase at 72.0 ± 12.2% efficiency. PEGPLA polymersomes demonstrate limited release at physiologic pH (7.4), with a burst release at the acidic pH (4.8) of the lysosome. PEGPLA polymersomes facilitate delivery of active β-galactosidase to an in vitro model of GM1 gangliosidosis. Conclusion: The foundation has been laid for testing of PEGPLA polymersomes to deliver enzymatic treatments to the brain in lysosomal storage disorders for the first time.

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2017-0221

Reference57 articles.

1. Prevalence of Lysosomal Storage Disorders

2. Clinical approach to inherited metabolic disorders in neonates: an overview

3. Gene therapy for lysosomal storage disorders

4. New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders

5. LYSOSOMAL STORAGE DISEASES

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing enzyme-responsive polymersomes for protein-based therapies;Nanomedicine;2024-01-25

2. Biocatalytic membranes with crosslinked enzyme aggregates for micropollutant removal;Chemical Engineering Journal;2024-01

3. Nanomedicines to treat rare neurological disorders: The case of Krabbe disease;Advanced Drug Delivery Reviews;2023-12

4. Hydrogel Delivery Device for the In Vitro and In Vivo Sustained Release of Active rhGALNS Enzyme;Pharmaceuticals;2023-06-27

5. The Impact of MiR-33a-5p Inhibition in Pro-Inflammatory Endothelial Cells;Diseases;2023-06-24